Mozobil (plerixafor, AMD-3100)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Mozobil |
| Generic Name: | plerixafor |
| Code Name: | AMD-3100 |
| Company: | Genzyme |
| FDA Clinical Phase: | Approved for use with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into the peripheral blood for collection and subsequent autologous transplantation in multiple myeloma patients |
Description:
Mozobil is a member of a new class of medications called "chemokine inhibitors". The drug triggers the movement of stem cells out of the bone marrow into the blood stream. Larger stem cell doses for transplantation are correlated to faster recovery times after high dose chemotherapy followed with stem cell transplantation.
Clinical Trials:
Currently, there are several open clinical studies involving Mozobil.
Source: ClinicalTrials.gov, Multiple Myeloma AND Mozobil, http://www.clinicaltrial.gov/ct2/results?term=multiple+myeloma+AND+Mozobil (as of September 4, 2008)
Related Articles:
- ECT-001 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation By U.S. FDA
- Number And Type Of Stem Cell Transplants Carried Out Each Year For Multiple Myeloma Vary Markedly Across U.S. Cancer Centers
- Researchers Shed More Light On Risk Of MGUS In Close Relatives Of People With Multiple Myeloma
- Adding Clarithromycin To Velcade-Based Myeloma Treatment Regimen Fails To Increase Efficacy While Markedly Increasing Side Effects
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
